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The systemic delivery of [E1] adenoviral (Ad) vectors encoding a transgene results in efficient viral uptake and abundant transgene
expression in the liver. However, [E1]Ad vector persistence is transient due to cytotoxic T lymphocyte (CTL)-mediated loss of the Ad-
infected cells. Our laboratory has previously demonstrated that additional modifications to the [E1]Ad vector genome, by deletion of the Ad
E2b genes, significantly decreased virus-genome-derived gene expression and simultaneously improved the long-term performance of the
resultant [E1, E2b]Ad vector. In this study, we confirmed that [E1, E2b]Ad vector genomes could persist equally well in C57Bl/6 or
Balb/c mouse hepatocytes. Despite vector genome persistence, we observed a strain-dependent variability in the duration of CMVenhancer/
promoter-driven transgene expression in the liver. While Balb/c mice rapidly shut down [E1, E2b]Ad-derived transgene expression, C57Bl/
6 mice allowed for prolonged transgene expression. This occurred even when both strains were crossed into a severe combined immune-
deficient background, demonstrating that host adaptive immune responses are not responsible for the phenomenon. Furthermore, differential
methylation of the CMV enhancer/promoter was also not demonstrated in either strain of mouse, eliminating this mechanism as causative.
Thus, alternative mechanisms for this phenomenon are discussed.
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Introduction recombinant protein and to viral encoded proteins, manifest-Gene transfer utilizing adenoviral (Ad) vectors has a
tremendous potential for the treatment of genetic diseases
because these vectors have the ability to efficiently infect
nonreplicating, differentiated cells in vivo, including liver,
lung, muscle, and nervous system cell types. Intravenous
injections of these vectors (encoding a gene of interest or
transgene) have been shown to result in highly efficient
recombinant gene expression in hepatocytes, which is one of
the best-characterized systems of Ad-vector-mediated gene
therapy. Although Ad vectors are widely used in gene
transfer techniques, a major limitation, not unique to these
vectors, is the induction of an immune response both to the0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.04.032
* Corresponding author. Duke University Medical Center, Box 2618,
MSRB, Durham, NC 27710. Fax: +1-919-684-2362.
E-mail address: amalf001@mc.duke.edu (A. Amalfitano).ing as a rapid loss of transgene expression. Gene transfer
using first-generation Ad vectors deleted for the E1 gene
([E1]Ad) and encoding bacterial h-galactosidase (LacZ)
has resulted in strong host immune responses, characterized
by the infiltration of mononuclear cells to the sites of viral
transduction that quickly eliminated vector-infected cells
(Gao et al., 1996; Michou et al., 1997a; Morral et al.,
1997; Schowalter et al., 1999; Yang et al., 1996). To decrease
immune responses to, and toxicity from, Ad viral backbone
derived gene expression, our group has further engineered
Ad vectors by deleting both the E1 and the E2b regions
(DNA polymerase and preterminal protein genes) of the viral
genome. In vitro studies using these multiply deleted vectors
have shown that they have a significantly decreased potential
to both replicate and express viral gene functions when
directly compared to [E1]Ad vectors (Amalfitano et al.,
1998). Our group has also demonstrated the long-term
persistence in vivo of modified [E1, E2b]Ad vectors
Fig. 1. Relative quantitative PCR (RQ-PCR) analysis of vector genome
persistence in different mouse strains. One hundred nanograms of total
genomic DNA from liver tissues of immunocompetent C57Bl/6, or Balb/c
mice injected with 1–1.5  1011 particles of [E1, E2b] CMV LacZ Ad
vectors was subjected to RQ-PCR analysis for the detection of Ad vector
LacZ sequences at 3, 21, and 42 dpi as described in Materials and methods.
R.S. Everett et al. / Virology 325 (2004) 96–105 97encoding the bacterial h-galactosidase transgene (LacZ) or
other genes in nontolerant, immunocompetent animal mod-
els (Ding et al., 2001, 2002; Harris et al., 2002; Hu et al.,
1999; Luebke et al., 2001; Everett et al., 2003).
We note that some groups have suggested that Balb/c
mice may be inherently more difficult to transduce long
term with Ad vectors, possibly because this strain of mouse
may have a more vigorous ‘‘immune response’’ than that
noted in other strains of mice, such as C57Bl/6 mice. We
therefore tested whether the improved [E1, E2b]Ad
vector platform could persist in Balb/c mice as effectively
as in other strains of mice. While evaluating this hypothesis,
we uncovered a strain-specific variability in the rate of
inactivation of the human CMV enhancer/promoter element
(when utilized to drive transgene expression from an Ad
vector backbone), despite the equivalent long-term persis-
tence of the modified Ad vector genome in the liver tissues
of both strains of mice.Each column represents the average hepatic adenoviral DNA content
(adenoviral genome copies/1  104 hepatocytes) at 3, 21, and 42 days
postinjection. Error bars represent the standard deviation.Results
Persistence of [E1, E2b] CMV LacZ Ad vectors in mouse
liver
To test whether modified Ad vectors could persist in
diverse strains of mice, 1–1.5  1011 particles of an [E1,
E2b] CMV LacZ Ad vector was intravenously injected
into C57Bl/6, Balb/c, and severe combined immune defi-
cient SCID mice on a C57Bl/6 or Balb/c background (SCID-
C57Bl/6 and SCID/Balb/c). To determine the persistence
of vector genomes in transduced heptatocytes in the C57Bl/6
or Balb/c mice, genomic DNA from liver tissues was
subjected to relative quantitative PCR (RQ-PCR) and den-
sitometric analyses at various times after injection of the
vector (Fig. 1). Our data confirmed the intrahepatic persist-
ence of the Ad vector genomes in each of the mouse strains
injected, as vector DNA was stably detected up to 42 days
post injection (dpi), the duration of this experiment.
Specifically, the data demonstrated that at 3 dpi, all
animals had more than one copy of the vector genome per
hepatocyte, averaging 5 copies per hepatocyte in C57Bl/6
mice, and 1.3 copies per hepatocyte in Balb/c mice. By 42
dpi, [E1, E2b]Ad vector genomes were still persistent in
the C57BL/6 and Balb/c strains of mice, with 100% of the
Ad genome copy number seen at 3 dpi still persistent in
C57Bl/6 mice at 42 dpi, and 73% of the initial [E1,
E2b]Ad vector genomes present in Balb/c mice at 42 dpi.
This result demonstrated that the hepatic persistence of [E1,
E2b]Ad vector genomes appears to be independent of
mouse strain differences. This result is in dramatic contrast
to results noted by others when similar experiments were
performed utilizing [E1]Ad vectors (Michou et al., 1997a;
Schowalter et al., 1999). The persistence of the [E1,
E2b]Ad vector genomes in the mouse strains was further
confirmed by Southern blot analyses (data not shown).Differential expression of the LacZ transgene in the different
strains
Because the Ad vector genomes were detected up to 42
dpi in the two strains of mice, we next evaluated transgene
expression derived from the persistent vector genomes by
multiple analyses of LacZ protein and LacZ-specific mRNA
transcript levels. In situ analysis of X-gal-stained sections of
liver tissue showed that despite the persistence of the vector
genomes in each strain of mouse, LacZ transgene expression
waned in both strains, but much more quickly in the Balb/c
liver tissues (Fig. 2). Extensive blue staining is observed
throughout the livers of each of the strains of mice at 3 dpi,
suggesting that the numbers of hepatocytes transduced
within the livers of each strain of mouse had been success-
fully and nearly equivalently transduced initially with the
[E1, E2b]Ad CMV-LacZ vector. In contrast, we could not
detect any LacZ-positive hepatocytes in the livers of Balb/c
mice beyond 3 dpi, indicating a rapid loss of transgene
expression in these mice. In contrast, the numbers of hep-
atocytes expressing LacZ diminished only slightly in C57Bl/
6 mice by 21 dpi, with a more dramatic decrease in LacZ-
positive hepatocytes noted by 42 dpi.
To further investigate these findings, we performed
direct measurements of LacZ levels in protein extracts
derived from the livers of injected and control mice (Fig.
3). Consistent with the in situ analyses, LacZ activity was
detected in each of the strains of mice at 3 dpi, but LacZ
activity diminished to undetectable levels in Balb/c mice
by 21 dpi. Although LacZ activity was detected in C57Bl/
6 mice at all three time points by X-gal staining of the
liver tissues, quantitative assessment of LacZ activity did
demonstrate that there was a significant decrease (P <
0.001) in LacZ levels by 21 dpi as compared to 3 dpi
Fig. 2. Immunohistochemical detection of LacZ expression in liver sections from injected and control mice as visualized by X-gal staining. Liver sections from
mice injected with 1–1.5  1011 particles of [E1, E2b] CMV LacZ Ad vectors, and euthanized at 3 days (n = 3), 3 weeks (n = 3 for SCID-Balb/c mice, n = 4
for SCID-C57Bl/6 mice, and n = 5 for C57Bl/6 and Balb/c mice), and 6 weeks (n = 4 for C57Bl/6, Balb/c, and SCID-C57Bl/6 mice) postinjection, and from
control mice that received PBS alone. In situ LacZ expression was not determined at 6 weeks postinjection in SCID-Balb/c mice. Liver tissue fixed in 0.5%
glutaraldehyde was sectioned and analyzed for the presence of LacZ. Blue staining indicates the presence of LacZ protein. Each panel represents an individual
animal, and is reflective of the patterns seen in all animals analyzed at these time points.
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42 dpi.
The species-specific pattern of expression of the LacZ
transgene in C57Bl/6 and Balb/c mice was further con-
firmed by relative quantitative RT-PCR (RQ RT-PCR)
analysis (Fig. 4). Densitometric analyses of the RT-PCR
products confirmed the presence of LacZ mRNA in each of
the mouse strains at 3 dpi, followed by a decreased overall
amount of LacZ-specific mRNA over time. This analysis
correlated with the X-gal staining data (Fig. 2), as the
numbers of X-gal-positive hepatocytes in liver sections
correlated with the relative amounts of LacZ mRNA tran-
scripts detected by RT-PCR. Importantly, LacZ transcripts
were undetectable in liver RNA derived from [E1,
E2b]Ad vector injected Balb/c mice after 3 dpi, indicating
a very rapid shutdown of transgene expression in the
hepatocytes of this mouse strain. In contrast, C57Bl/6 mice
displayed a significantly slower rate of attenuation of LacZtransgene expression, with LacZ mRNA being detected at
21 dpi, although 20% lower than the mRNA levels at 3
dpi, and LacZ mRNA levels that were 85% less than the 3
dpi levels by 42 dpi. Thus, there was a differential rate of
CMV enhancer/promoter-mediated shutdown of LacZ ex-
pression in the two strains of mice over time. This data was
further confirmed by Northern blot analysis (data not
shown).
To confirm that adapative immune responses were not
significantly influencing these results, we also injected
severe combined immune-deficient (SCID) C57Bl/6 and
Balb/c mice with identical amounts of the [E1,
E2b]AdLacZ vector. While at 3 dpi, both strains of mice
again demonstrated high-level hepatic transduction (higher
than that noted in the non-SCID strains) X-gal staining of
liver tissues again confirmed a more rapid loss of X-gal
stained hepatocytes by 21 dpi in the Balb/c + SCID mice
relative to levels measured in identically injected C57Bl/6 +
Fig. 3. Liver LacZ levels. LacZ concentration quantitated as nanograms of
LacZ per microgram of liver-derived protein, and expressed on a
logarithmic scale. Hepatic tissues were collected from control mice and
mice that received 1–1.5  1011 particles of [E1, E2b] CMV LacZ Ad
vectors. Mice were euthanized at three different time points, i.e., 3 days
(n = 3), 3 weeks (n = 3 for SCID-Balb/c mice, n = 4 for SCID-C57Bl/6
mice, and n = 5 for C57Bl/6 and Balb/c mice), and 6 weeks (n = 4 for
C57Bl/6, Balb/c and SCID-C57Bl/6 mice) postinjection, and LacZ
activity determined in liver protein extracts. LacZ levels were not
determined at 6 weeks postinjection in SCID-Balb/c mice (denoted by
ND). Each column represents the average LacZ activity level for each
mouse strain. Values below the detection limit of the assay are denoted by
an asterisk (*).
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corroborated by hepatic LacZ activity measurements in the
two strains of SCID mice (Fig. 3).Fig. 4. Relative quantitative RT-PCR (RQ RT-PCR) analyses of the
amounts of LacZ-specific transcripts present in liver tissues of C57Bl/6 or
Balb/c mice following transduction with [E1 E2b] CMV LacZ Ad
vectors. Mice injected with 1–1.5  1011 particles of the modified Ad
vectors were euthanized at 3 days (n = 3), 3 weeks (n = 5), and 6 weeks (n =
4) postinjection. DNase-I-treated total liver RNA (2.5 Ag) from each animal
was subjected to RQ RT-PCR for the detection of LacZ mRNA transcripts,
as described in Materials and methods. Values below the detection limit of
the assay are denoted by an asterisk (*).Anti-LacZ antibody detection by ELISA
Because the modified Ad vector genomes persisted
relatively equivalently in both C57Bl/6 and Balb/c mice,
we examined the nature of the immune response to the
LacZ transgene. One possibility may have been that the
LacZ protein was being perceived as foreign by only one
and not the other mouse strain, relative to an equivalent
transduction of the LacZ gene by the [E1, E2b]Ad
vector. We evaluated for this possibility by performing
an ELISA to measure the amount of anti-LacZ antibodies
in the plasma of Ad-injected and control animals (Fig.
5). We found that as expected, the immunocompetent
C57Bl/6 and Balb/c mice both produced high and
sustained levels of anti-LacZ antibodies by 21 dpi, with
the antibodies still detected at 42dpi. As a negative
control antibodies were not detected in the plasma of
SCID mice on a C57Bl/6 background (SCID-C57Bl/6)
mice that had been equivalently injected. Thus, although
both the C57Bl/6 and Balb/c mice perceived the LacZ
transgene as being a foreign antigen, this did not affect
the ability of the [E1, E2b]Ad vector genomes to
persist long term in the hepatocytes of the two strains of
mice.
Bisulfite modification and sequencing of the CMV promoter
for detection of de novo methylation
Since it was demonstrated by Prosch et al. (1996) that
methylation of the cytosines in the CpG dinucleotides of
the human CMV modulator/enhancer/promoter resulted
in the loss of CMV promoter activity in vitro, we exam-
ined the in vivo methylation status of the CMV promoter
from the injected Ad vector genomes at 3 and 21 dpi in the
y 325 (2004) 96–105 99Fig. 5. Murine antibodies directed against LacZ. Plasma was isolated from
blood samples of control mice and mice injected with [E1, E2b] CMV
LacZ Ad vectors. Plasma collected at 1, 21, and 42 days postinjection were
tested by ELISA for anti-LacZ antibodies as described in Materials and
methods. This figure summarizes the relative amounts of antibodies to LacZ
as a function of time.
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mice (Fig. 6). Liver DNA from 1 to 3 mice was isolated
from each strain at both 3 dpi and 21 dpi and subjected to
bisulfite treatment and subsequent sequencing as described
in the materials and methods section. Analysis of the entire
region from 575 to + 13 of the CMV enhancer/promoter
region present in both vectors (Fig. 6A) revealed complete
conversion of all cytosine residues, indicating a lack of
methylation throughout this region in all strains of mice so
analyzed, at both the 3 and 21 dpi time points (Fig. 6B).
Our results indicated that the loss of transgene expression
(nor the differential rate of loss of CMV promoter activity)
was not due to de novo, differential methylation of the
CMV promoter.Fig. 6. Methylation status of CMV enhancer/promoter in adenovirus-transduced
enhancer/promoter sequence shown was analyzed in its entirety for the presence
transcription start site at +1. CG dinucleotides are underlined. (B) Methylation ana
mice was isolated at 3 and 21 dpi, bisulfite treated, PCR amplified, and sequenced w
enhancer. Bisulfite treatment deaminates unmethylated CG dinucleotides and conv
Methylated CG dinucleotides will be blocked from deamination and remain as cyt
from nucleotides 525 to 501 of the CMVenhancer/promoter are presented. Cyt
CG cytosines (diamonds) will not be methylated and therefore serve as a positiv
depicted are representative of all the results we obtained after similar analysis of the
1; C57Bl/6 (21 dpi), n = 2; Balb/c (3 dpi), n = 3; Balb/c (21 dpi), n = 3; SCID+C57B
3; SCID+Balb/c (21 dpi), n = 3.Discussion
Adenoviruses (Ad) are highly attractive vectors for the in
vivo transfer of genetic information. Several groups have
shown that in vivo transduction with first-generation
[E1]Ad vectors encoding a variety of transgenes results
in the rapid elimination of the cells infected by the vector, in
part due to cytotoxic T-lymphocyte (CTL)-mediated im-
mune responses (Gao et al., 1996; Michou et al., 1997a;
Morral et al., 1997). This is because despite the deletion of
the E1 region, first-generation Ad vectors still express low
levels of viral early genes such as the polymerase, preter-
minal protein, E2a and E4 genes, as well as late genes such
as the penton, hexon, and fiber proteins. It is likely that thelivers of various mice. (A) CMV promoter/enhancer sequence. The CMV
of methylation using bisulfite sequencing. The large ‘‘T’’ represents the
lysis. As described in Materials and methods, total liver DNA from injected
ith several primers to analyze the methylation status of the CMV promoter/
erts them to uracils (read as thymines after PCR and sequencing reactions).
osines. Representative samples are shown for each mouse strain; the results
osines belonging to CG dinucleotides are indicated by arrowheads. All non-
e control to ensure that the bisulfite conversion was complete. The results
entire CMVenhancer/promoter sequence depicted in A. For C57 (3dpi), n =
l/6 (3 dpi), n = 2, SCID+C57Bl/6 (21 dpi), n = 3; SCID + Balb/c (3 dpi), n =
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uted to immune recognition and elimination of vector
infected cells, as well as vector induced toxicity within
transduced cells. Michou et al. (1997b) demonstrated the
rapid elimination of [E1]Ad vector genomes from trans-
duced liver tissues of C57Bl/6 and Balb/c mice, a result that
positively correlated with the rapid loss of LacZ expression
noted in the hepatocytes of the mice (Michou et al., 1997b).
In contrast to the previous report, several groups have noted
that prolonged expression of some genes (transduced via
[E1]Ad vectors) can be achieved in C57Bl/6 mice, includ-
ing human CFTR, human alpha-1-antitrypsin (hAAT), hu-
man VLDL, and human Factor IX (Barr et al., 1995;
Kozarsky et al., 1996; Michou et al., 1997; Scaria et al.,
1998). Barr et al. (1995) noted that although hAAT expres-
sion was prolonged in C57Bl/6 mice, the same result could
not be achieved in Balb/c mice. Studies such as those
performed by Schowalter et al. (1999) subsequently con-
firmed that the cause for the loss of hAAT transgene
expression in Balb/c mice was due to a rapid loss of
[E1]AdhAAT vector genomes by 40 dpi (Schowalter et
al., 1999). The authors further reported that loss of vector
genome and hAAT mRNA elimination was accompanied by
liver toxicity, and suggested that apoptosis of the [E1]Ad-
hAAT-transduced hepatocytes resulted in the rapid loss of
hepatocytes containing [E1]Ad vector genomes (Schowal-
ter et al., 1999).
In total, these multiple observations have led to a general
consensus view that Balb/c mice have an intrinsically more
vigorous cytotoxic T cell immune response to [E1]Ad-
mediated transfer of transgenes, as compared to similar
attempts performed in C57Bl/6 mice. The fact that C57Bl/
6 mice have been long known to exhibit predominantly Th1
immune responses [higher levels of IFNg (a Th1 cytokine)
and IP-10 in the spleens of normal C57Bl/6 mice] while
Balb/c mice favor Th2 responses, [spleens from normal
Balb/c mice have higher amounts of IFNh, TGFh1, chemo-
kine receptor 3 (CCR3), and CXC chemokine receptor 4
(CXCR4)] is but one of several possible reasons for the
widely discrepant responses to Ad-mediated gene delivery
noted in the two mouse strains (Guler et al., 1996; Reiner
and Locksley, 1995; Charles et al., 1999a). Interestingly,
strain-specific differences in the susceptibility or resistance
to mouse adenovirus type 1 (MAV-1) has also been ob-
served in C57Bl/6 and Balb/c mice, as well as in other
mouse strains (Charles et al., 1999b; Kring et al., 1995,
Spindler et al., 2001). These observations further bolster the
view that intrinsic differences between different mouse
strains play an important role in responses to infection with
adenoviruses.
In this study, we examined whether the previously
recognized immunological differences in C57Bl/6 and
Balb/c mice would influence [E1, E2b]Ad vector ge-
nome persistence, and/or durations of transgene expression
derived from the vectors. This line of investigation seemed
logical to pursue, as our group has previously demonstratedthat [E1, E2b]Ad-vector-mediated transfer of several
genes into a variety of animal models can result in
relatively longer vector genome persistence and foreign
transgene expression, as compared to similar attempts with
first-generation [E1]Ad vectors encoding identical trans-
genes (Ding et al., 2002; Harris et al., 2002; Hu et al., 1999;
Luebke et al., 2001; Everett, et al., 2003). We utilized an
[E1, E2b]Ad vector encoding the LacZ transgene, whose
expression was driven by the human CMV enhancer/pro-
moter element. We then assessed the vectors persistence and
durability of LacZ expression in the liver tissues of immuno-
competent C57Bl/6 and Balb/c mice. Ad vector genomes
were indeed detected by RQ-PCR analyses in both strains
of mice up to 42 dpi, the maximum time point in this study,
confirming that [E1, E2b]Ad vectors can persist as
effectively in the livers of Balb/c mice as in the livers of
C57Bl/6 mice. The ability of the [E1, E2b]Ad vector ge-
nome to persist was impressive, because both the C57Bl/6
and Balb/c mice perceived the LacZ gene expressed by the
vector as foreign, as evidenced by the presence of high
titers of anti-LacZ antibodies in these mice at time points
beyond 21 dpi.
Despite the persistence of the vector genome in the livers
of both strains of mice, we noted a precipitous loss of LacZ
expression in Balb/c mouse liver, relative to the slower
rate of loss of LacZ expression in the livers of C57Bl/6
mice. The persistence of the [E1, E2b]Ad vector genomes
allowed our group to confirm that the levels and longevity
of CMV-driven transgene expression in the livers of mice
can be subject to strain-specific influences, especially when
Balb/c mice are used as the indicator organism. Because
we made similar observations in C57Bl/6 + SCID and Balb/
c + SCID mice, we confirmed that differential adaptive
immune responses was not the cause for the differential rate
of loss of LacZ expression noted.
One possible explanation for these results is that the
differential elimination of transgene expression may have
been due to a strain-specific differential down-regulation of
the CMV enhancer/promoter element utilized to drive the
LacZ gene in our [E1, E2b]Ad vector. Although it has
been demonstrated that methylation of the CpG dinucleo-
tides in the human CMV modulator/enhancer/promoter
results in transcriptional inactivation in vitro (Prosch et al.,
1999), our in vivo analysis of the methylation status of the
CMV promoter from the intrahepatic Ad vector genomes at
3 and 21 dpi in all four strains of mice showed no evidence
of de novo methylation of this promoter. This suggests that
mechanisms other than promoter methylation are responsi-
ble for the (differential) loss of hepatic transgene expression
in this model system.
As a result, we are left to speculate on alternative reasons
to explain this phenomenon of strain-specific rates of
promoter shutdown. One possibility may be a differential
rate of down-regulation of transcriptional factors equiva-
lently induced by Ad infection, i.e., Balb/c mice may
rapidly extinguish expression of such factors relative to
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factor NFnB. NFnB induction does occur after Ad vector
transduction of murine hepatocytes. Afterwards, waning
levels of activated NF-kB positively correlated with the
slow loss of transcriptional activity of the CMV enhancer/
promoter noted in the livers of [E1]Ad vector-infected
SCID mice (Loser et al., 1998). Down-regulation of the
CMV enhancer/promoter has also been correlated with
induction of high levels of the pro-inflammatory cytokines
TNFa and IFNg; therefore, strain-specific differences in the
induction of these cytokines may also be influencing our
observations (Qin et al., 1997; Sung et al., 2001).
Injection of [E1, E2b]Ad vectors encoding trans-
genes under the transcriptional control of the CMV
enhancer/promoter will allow for measures of CMV
enhancer/promoter activity to act as an ‘‘indicator’’ of
the multiple immune responses elicited in the recipient
mouse. This will allow for investigation of these path-
ways, and how these pathways may diverge in different
strains of mice, without being influenced by differential
(and strain specific) adaptive immune responses to the Ad
vector itself. These experiments may yield information
that could enable the isolation of new promoters for gene
therapy, which enable both high-level and persistent
hepatic expression of transgenes in a variety of genetic
backgrounds.Materials and methods
Construction and systemic administration of [E1, E2b]
CMV LacZ adenoviral vectors into mice
The construction and isolation of the adenoviral (Ad)
vector [E1, E2b] CMV LacZ was achieved as previously
described (Everett et al., 2003). This vector, multiply
deleted for the early region 1 (E1), and the E2b region
(DNA polymerase and preterminal protein (pTP) genes)
was engineered to utilize a 576-bp cytomegalovirus (CMV)
promoter that drives the expression of the bacterial h-
galactosidase (LacZ) transgene. Mice ranging in age from
6 to 10 weeks old were selected for this study. Vector
preparations were titered for particle number concentrations
as previously described (Ding et al., 2001). Particles of the
recombinant adenovirus (1–1.5  1011) were intravenously
injected into the systemic circulation of C57BL/6, Balb/c
mice (Jackson Laboratory, Bar Harbor, ME), and severe
combined immune deficient (SCID) mice (on a C57Bl/6
background) as previously described (Hodges et al., 2000).
The stock of virus used in this study was obtained from a
single clone, and confirmed to be lacking replication-
competent adenovirus (RCA) using a PCR specific for
detection of Ad E1 gene sequences, essentially as described
by others (Lochmuller et al., 1994). Control mice were
injected with the vehicle (phosphate-buffered saline) only.
Injected animals were euthanized at 3 days (n = 3/strain), 21days (n = 5 in C57Bl/6 and Balb/c mice, n = 4 in SCID-
C57Bl/6 mice, and n = 3 in SCID-Balb/c mice) and 42 days
(n = 4/strain) post injection (dpi). Liver samples were
collected and portions analyzed as described below. Plasma
was collected from all animals at 1, 3, 21, and 42 dpi for
immunological assays. All animal procedures were ap-
proved by the Duke University Institutional Animal Care
and Use Committee.
DNA isolation and analysis
DNA was isolated from liver homogenates to determine
the persistence of the Ad vector genome in transduced
hepatocytes. Liver samples were digested in TNES buffer
and Proteinase K (20 mg/ml) buffer as previously described
(Hu et al., 1999). The samples were centrifuged at 13,000
rpm, supernatants collected, and incubated with RNase A
(10mg/ml) for 2 h at 37 jC. Following incubation, 5 M
NaCl was added to each tube and the solution passed three
times through a 28G1/2 insulin syringe to shear high
molecular weight DNA. A 24:1 solution of chloroform/
isoamyl alcohol was added to each sample and the mixture
was centrifuged for 4 min at maximum speed on a tabletop
centrifuge. The upper aqueous phase of the suspensions
were collected, 0.7 volumes of isopropyl alcohol added,
and the solution centrifuged for 15 min at maximum speed.
The DNA pellet was washed in 70% ethanol and resus-
pended in 10mM Tris–Cl, pH 8.5. PCR: 100 ng of total
genomic DNA from each of the mice was subjected to
multiplex relative quantitative polymerase chain reaction
(RQ-PCR) using primers specific to LacZ sequences in the
[E1, E2b] CMV LacZ vector genome (5V-ATCCTCTG-
C AT G G T C A G G T C - 3 V f o r w a r d , a n d 5 V-
CTGGGCCTGATTCATTCC-3V reverse, PCR product of
315 bp). PCR specific for the 18S rRNA gene (product
489 bp), amplified by using 18S-specific primers and
competimers supplied by the manufacturer (Ambion Inc.)
at a ratio of 4:6, respectively, were used as an invariant
endogenous control PCR to compensate for variations in
DNA quality, isolation, and amplification. With this ratio of
primers to competimers, the amount of 18S-amplified PCR
product was within the same linear range as the LacZ
product. DNA isolated from mock-infected mouse liver
DNA was spiked with decreasing amounts of a LacZ-
encoding plasmid, generating a copy number standard
curve consisting of 3  104, 2  104, 1  104, 0.75 
104, 0.5  104, and 0.25  104 Ad genomes/1  104
hepatocytes. Amplification of the PCR products was con-
ducted in a reaction volume of 20 Al under the following
conditions: 94 jC for 4 min followed by 23 cycles of 94 jC
for 30 s, 56 jC for 20 s, and 72 jC for 1 min. PCR products
were run through a 1.5% agarose gel and an image of the gel
digitally captured using the Kodak Digital Science 1D Image
Analysis Software (Eastman Kodak Company). Densitomet-
ric analyses of the PCR products were performed using
Scion Image and the level of the LacZ-specific PCR product
R.S. Everett et al. / Virologfor each sample was normalized to the 18S product, and
quantitated by comparison to the standard curves.
Southern blot analysis
Ten micrograms of total genomic DNA from injected and
control mice was digested with EcoRV and electrophoreti-
cally separated in a 0.7% agarose gel. DNA was then
transferred to a nylon membrane, UV cross-linked, and
hybridized to an Ad-specific, 9620 bp [a-32P]dCTP-labeled
DNA probe, as previously described (Amalfitano et al.,
1998). After hybridization, the membranes were exposed
to autoradiographic film, and vector genome quantitation
(using copy number standards generated from appropriate
amounts of Ad2 DNA added to mock-infected liver DNA
samples) was performed via densitometric analysis using the
Kodak Digital Science 1D Image Analysis Software (East-
man Kodak Company).
RNA isolation and analysis
Total RNA was extracted from 25 to 50 mg of liver
homogenates using the Total RNA Isolation System (Prom-
ega, Madison, WI) as per the manufacturer’s instructions.
Briefly, frozen liver samples were pulverized in a denaturing
solution (26 mM sodium citrate, pH 4.0; 0.5% N-lauryl
sarcosine, 0.125 M h-mercaptoethanol, 4 M guanidine thio-
cyanate) while cooled with liquid nitrogen. Sodium acetate (2
M) was added to a final concentration of 10% v/v, followed
by the addition of 10 volumes of phenol/chloroform/isoamyl
alcohol. Following centrifugation, the top aqueous phase was
removed and an equal volume of isopropanol added. The
precipitated RNA was pelleted by centrifugation, air-dried,
and dissolved in nuclease-free water.
RT-PCR
Following treatment of RNAwith DNase I, 2.5 Ag of total
liver RNA derived from injected and control mice was
subjected to relative quantitative reverse transcription poly-
merase chain reaction (RQ RT-PCR). Complementary DNA
(cDNA) was generated by the addition of 20 ng of random
primers (GIBCO-BRL) and M-MLV reverse transcriptase
(RT) (Invitrogen, Carlsbad, CA) in manufacturer-supplied
RT buffer at 42 jC for 1 h. Equivalent volumes (3 Al) of
cDNA derived from the RT reaction was subjected to PCR
amplification utilizing the same two sets of primers used for
quantitation of vector genome persistence by RQ-PCR (see
above). Thermal cycling conditions were as follows: 94 jC
for 4 min followed by 21 cycles of 94 jC for 30 sec, 55 jC
for 20 s, and 72 jC for 1 min. LacZ-specific transcripts were
quantitated via densitometric analyses of the RT-PCR prod-
ucts using the Kodak Digital Science 1D Image Analysis
Software (Eastman Kodak Company). The relative amounts
of LacZ mRNA in each sample were compared after nor-
malized for the amount of 18S rRNA present in the sample.Northern analysis
Ten micrograms of total RNAwas denatured and separat-
ed on a 3% agarose-formaldehyde gel as previously described
(Hu et al., 1999). RNAwas transferred to a nylon membrane,
UV cross-linked, and hybridized to a 3116-bp [a-32P]dCTP-
labeled LacZ-specific DNA probe. After hybridization, the
membrane was exposed to autoradiographic film and LacZ
transcripts were quantitated via densitometric analysis using
the Kodak Digital Science 1D Image Analysis Software
(Eastman Kodak Company). Relative amounts of LacZ
mRNA were determined from the ratio of LacZ mRNA to
the total RNA loaded for each sample. Total RNA present in
each sample was normalized to the amount of 18S rRNA in
that sample.
In situ X-gal staining of liver samples
Liver samples were snap-frozen in liquid nitrogen-cooled
isopentane. Eight-micrometer sections of the frozen tissue
were obtained after sectioning with a Leica cryomicrotome.
Cryosections were fixed in 0.5% glutaraldehyde/PBS solu-
tion followed by incubation in 1 mMMgCl2. The slides were
then incubated for 3 h at 37 jC in 5-bromo-4-chloro-3-
indolyl h-D-galactopyranoside (X-gal) for the detection of
bacterial h-galactosidase-mediated production of the chro-
mogenic substrate. The sections were then counterstained in
eosin, mounted in Permount, and images digitally captured
using the SPOT software package (Diagnostics Instruments,
Inc., Sterling Heights, MI).
Quantitation of LacZ levels in liver tissue
Total protein from liver tissues was isolated by grinding
the tissues in liquid nitrogen followed by incubation in lysis
buffer [(100 mM potassium phosphate, pH 7.8, 0.2% Triton
X-100, 0.5mM dithiothreitol (DTT)] and centrifugation at
13,000 rpm. A Bicinchoninic (BCA) protein assay kit
(Pierce, Rockford, IL) was used to determine protein con-
centration of the liver extracts. An equivalent volume of total
protein from each sample was incubated at 37 jC for 1 h with
1 mM MgCl2, 45 mM 2-mercaptoethanol, 0.264 Ag of o-
nitrophenyl h-D-galactopyranoside (ONPG) and 50 mM of
sodium phosphate solution at pH 7.5 per well. Sodium
carbonate (0.5 M) was added to each well to stop the
reaction, and the absorbance of each sample was read at a
wavelength of 415 nm. Known amounts of bacterial h-
galactosidase (Sigma, St. Louis, MO) were serially diluted
to generate a standard curve from which the amount of LacZ/
Ag of protein in each experimental sample was determined.
Bisulfite modification and sequencing of the CMV promoter
for detection of de novo methylation
Bisulfite treatment was carried out using the following
protocol. Two micrograms of genomic DNA samples were
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prepared 3 M NaOH was added to each sample and
incubated at 42 jC for 20 min. A saturated sodium bisulfite
solution was prepared by dissolving 5.4 g sodium bisulfite
(Sigma) in a total volume of 8 ml water and 0.22 g
hydroquinone (Sigma) in a total volume of 10 ml water.
(Sodium bisulfite and hydroquinone are stored under vacu-
um in the dark and exposure to light was minimized
throughout the experiment.) To the bisulfite solution, we
added 1.3 ml of 3 M NaOH, 500 Al of hydroquinone
solution, and 200 Al of water to create the final working
solution. Four hundred fifty microliters of this solution was
added to each denatured sample, overlaid with 2 drops of
mineral oil, and incubated at 55 jC for 4 h in the dark.
Samples were then desalted using the Wizard DNA Clean-
up System (Promega) according to manufacturer’s direc-
tions. Each sample was next eluted using 50 Al of 1 mM
Tris, pH 8.0, prewarmed to 80 jC. NaOH (3 M, 5.5 Al) was
added to the eluted sample and incubated for 20 min at 37
jC. DNA was then EtOH-precipitated and pellets resus-
pended in 20 Al of 1 mM Tris, pH 8.0.
PCR was performed using Platinum Taq (Invitrogen) on 2
Al of each sample incubated with the following primers:
ES1f 5V-GTG TAT ATA GGA AGT GAT AAT TTT-3V and
LacZ1r 5V-TCT AAC CTT CCT ATA ACC AAC T-3V. PCR
cycling parameters included denaturation at 95 jC for 30 s,
annealing at 58 jC for 30 s, and extension at 72 jC for 1 min,
each cycle repeated for a total of 35 cycles. Resulting PCR
products were purified with GenElute Minus EtBr Spin
Columns (Sigma) and 4 Al of the reaction products were
sequenced using the Thermo Sequenase Radiolabeled Ter-
minator Cycle Sequencing Kit (USB, Cleveland, OH) with
three additional primers to analyze the entirety of the CMV
promoter: Seq1f 5V-GAA TAA GAG GAA GTG AAA TTT
G-3V, ES2f 5V-GGA AAATTG AATAAG AGG AAG TG-3V
and cmvf3 5V-TTT ATG GGATTT TTT TAT TTG GTA G-
3V. Sequence cycling conditions for all primers were 95 jC/
30 s, 55 jC/30 s, 72 jC/1 min for 30 cycles.
Reaction products were then electrophoretically separat-
ed on a gel, and autoradiography performed to allow
visualization of the sequencing results. The conversion of
all non-CG dinucleotide cytosines serves as a positive
control to ensure that the initial DNA template underwent
complete deamination.
ELISA for the detection of antibodies to LacZ in the plasma
of mice
Ninety-six-well ELISA plates (Corning Incorporated,
NY) were coated overnight at 4 jC with bacterial h-galac-
tosidase (Roche Diagnostics, Indianapolis, IN) at a 1:250
dilution (1 Ag/well) in Dulbecco’s phosphate-buffered saline
(DPBS). The wells were blocked with DPBS + 2% bovine
serum albumin (BSA) and incubated for 90 min at 37 jC.
Plasma samples from injected and control mice, at a dilution
of 1:200, were added to the wells and incubated for 1 h at 37jC. After washing with DPBS + 0.2% Tween in DPBS, an
alkaline-phosphate conjugated sheep antimouse IgG second-
ary antibody at a 1:2500 dilution was added and incubated at
37 jC for 1 h. After incubation, wells were washed again and
the substrate solution p-nitrophenyl phosphate (Sigma) was
added and incubated at room temperature for 30 min. The
absorbance was then measured at 405 nm, and the results
plotted as absorbance values vs. time postinjection.Acknowledgments
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